7th Apr 2016 07:43
LONDON (Alliance News) - OptiBiotix Health PLC on Thursday said it has received positive results from the study undertaken to test cholesterol-reducing effects of its capsular supplement.
OptiBiotix said participants who took its capsular supplement showed a 7.2% reduction in low-density lipoprotein cholesterol compared to those taking placebos.
The tests showed a 12.4% reduction in LDL cholesterol in female volunteers and a 15% reduction for those aged 50-55.
The results, OptiBiotix said, provide early evidence its cholesterol-reducing treatment has commercial potential as a safe, easy-to-use and low-cost supplement.
"Given the market opportunity and limitations of existing products such as statins, the commercial potential for this product looks promising. Commercial discussions are progressing with potential partners best positioned to fully exploit the opportunity as a cholesterol and/or hypertension supplement, in isolation, or in combination with existing approaches," said Chief Executive Stephen O'Hara.
OptiBiotix shares were up 4.6% to 81.88 pence Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health